Can Recursion Pharmaceuticals Deliver on the Hype?

Technology-enabled drug discovery promises to increase the efficiency of drug development. By combining artificial intelligence, robotic labs, and sometimes supercomputers, the emerging field thinks it can find better drug candidates faster. If those assets progress through clinical trials more easily, then it can shave years and tens or even hundreds of millions of dollars off traditional drug development cycles. 

Recursion Pharmaceuticals  (RXRX) – Get Recursion Pharmaceuticals Inc. Report is one of the leading technology-enabled drug developers. The company’s pitch to investors includes many buzzy words and phrases. For example, the precommercial business aims to “industrialize drug discovery” with robotic labs. A unique “operating system” powered by “mapping biology” could yield tremendous efficiency gains, according to investor presentations.

Stacee R. Grigg

Next Post

What downturn? Investors remain bullish on HR tech as the Great Resignation slows – TechCrunch

Wed Jul 20 , 2022
Platforms, not position methods, could possibly guide the way The marketplace for HR tech, which operates the gamut from workforce management to applicant recruitment and tracking techniques, has verified remarkably resilient in the face of both equally pandemic and financial headwinds. In actuality, some would argue that it is specifically […]